Aventis Lantus launch

Executive Summary

Sales reps detailing the long-acting insulin product Lantus "reached 50% of the 56,0000 targeted physicians in the first week on the market," Aventis CEO Richard Markham says during Goldman Sachs conference June 13. Lantus was approved over a year ago, but launch was delayed until May 22 while Aventis built sufficient supplies. "Forty-seven out of 50 states have added Lantus to the Medicaid formularies already and we're confident that the other three will soon follow," Markham says. The drug was "approved [for] unrestricted access in the largest U.S. PBM"